164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors

Sharma, M. R., Carvajal, R. D., Hanna, G. J., Kang, Y. K., Lee, J., Lee, K. W., Li, B. T., Moore, K. N., Pegram, M., Rasco, D., Spira, A., Wang, D., Weinberg, B. A., Alonso, M., Fang, L., Husain, A., Kowanetz, M., Perez, E. A., & Dumbrava, E. I. (2021). 164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. Annals of Oncology, 32, S1453–S1454. https://doi.org/10.1016/j.annonc.2021.10.183

Authors:

Monica Sharma

Richard D. Carvajal

Glenn J. Hanna

Yoon‐Koo Kang

J. Lee

K.W. Lee

B.T. Li

Kathleen N. Moore

Mark D. Pegram

Drew Rasco

Alexander I. Spira